Uniqure (NASDAQ: EBIO) and Eleven Biotherapeutics (NASDAQ:EBIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.
Insider & Institutional Ownership
59.3% of Uniqure shares are owned by institutional investors. Comparatively, 14.0% of Eleven Biotherapeutics shares are owned by institutional investors. 2.0% of Uniqure shares are owned by company insiders. Comparatively, 28.7% of Eleven Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of current recommendations for Uniqure and Eleven Biotherapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Uniqure presently has a consensus price target of $45.00, suggesting a potential upside of 5.56%. Eleven Biotherapeutics has a consensus price target of $5.00, suggesting a potential upside of 51.98%. Given Eleven Biotherapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Eleven Biotherapeutics is more favorable than Uniqure.
This table compares Uniqure and Eleven Biotherapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Uniqure and Eleven Biotherapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Uniqure||$13.11 million||120.77||-$79.26 million||($2.94)||-14.50|
|Eleven Biotherapeutics||$430,000.00||365.65||-$29.02 million||($1.11)||-2.96|
Eleven Biotherapeutics has lower revenue, but higher earnings than Uniqure. Uniqure is trading at a lower price-to-earnings ratio than Eleven Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Uniqure has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, Eleven Biotherapeutics has a beta of 2.75, suggesting that its share price is 175% more volatile than the S&P 500.
Eleven Biotherapeutics beats Uniqure on 10 of the 14 factors compared between the two stocks.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. Eleven Biotherapeutics, Inc. has a cooperative research and development agreement with the National Cancer Institute on the development of the company's targeted therapeutic, Vicinium in combination with AstraZeneca's immune checkpoint inhibitor, ImfinziTM (durvalumab), for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.